DISCOVERIES (ISSN 2359-7232), 2014, Oct-Dec

CITATION: 
Andrei S, Iorgoveanu C. New perspective in heart failure management: could myosin activators be the answer? Discoveries 2014, Oct-Dec; 2(4): e33. DOI: 10.15190/d.2014.25

Submitted: December 08th, 2014; Revised: December 22nd, 2014; Accepted: December 30th, 2014; Published: December 31st, 2014;

GO BACK to 2014, October-December issue 
GO BACK to DISCOVERIES

New perspective in heart failure management: could myosin activators be the answer?

Stefan Andrei (1,*), Corina Iorgoveanu (2)

(1) “CNHO des Quinze-Vingts, Service de Médecine Interne, Paris, France; 
(2) CC Iliescu Institute of Cardiovascular Diseases, Cardiology, Bucharest, Romania; 

*Correspondence to: Stefan Andrei, MD, CNHO des Quinze-Vingts, Service de Médecine Interne, 28, Rue de Charenton, 75 571 Paris Cedex 12, France; Email: stefanmandrei@gmail.com;

Abstract

Heart failure is a worldwide leading cause of hospital admissions. There is a critical need for new methods of management in acute heart failure.  The current drug panel available in the treatment of hemodinamically unstable patients is not only limited, but it is also associated with deleterious side effects. Discoveries in the heart failure field seemed to lack an adequate answer and a change in paradigm may be necessary. The cardiac myosin activator omecamtiv mecarbil is a new therapeutic approach that improves the myocardial contractility through an innovative mechanism, avoiding the harmful effects of currently used inotropic agents.  Several studies provided us with promising results, but further scientific proofs are needed.

Access full text of the manuscript here: See full text (pdf)

References

1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;  380(9859):2095-128. 

2. Lim S, Vos T, Flaxman AD,  Danaei G, Shibuya K, Adair-Rohani H et al. A comparativerisk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859):2224-60.

3. WHO - Cardiovascular diseases Fact Sheet no 317, 2013.

4. McMurray JV, Adamopoulos S, Anker SD, Auricchio A,  Böhm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur Heart J 2012; 33(14):1787-847.

5. McMurray JJV. Clinical practice: Systolic heart failure. N Engl J Med 2010; 362(3):228-38. 

6. Francis GS, Bartos JA and Adatya S. Inotropes. J Am Coll Cardiol 2014; 63(20):2069-78.

7. Tirziu D, Giordano FJ, Simons M. Cell Communications in the Heart. Circulation 2010; 122(9):928-37.

8. Cooper GM. Actin, myosin and cell movement in The Cell: A Molecular Approach. (Sinauer Associates, 2000).

9. Karp G, Cytoskeleton and cell motility in Cell and molecular biology 6th Edition (John Wiley & Sons Inc, 2009).

10. Fabiato A. Calcium-induced release of calcium from the cardiac sarcoplasmic reticulum. Am J Physiol 1983; Jul 245, C1–C4.

11. Choong-Chin L and  Dzau VJ. Calcium cycling in the cardiomyocyte. Nat Rev Genet 2004; November, 811–825.

12. Suzuki T, Palmer BM, James J, Wang Y, Chen Z, VanBuren P et al. Effects of cardiac myosin isoform variation on myofilament function and crossbridge kinetics in transgenic rabbits. Circ Hear Fail 2009;  2(4):334-41;

13. Rubin S and Pondok T. Inotropic therapy in clinical practice in Heart failure -pharmacolog management (ed.  Feldman A) 104–105 (Blackwell publishing, 2006).

14. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995; 38(2):167-80.

15. Kass DA, Solaro RJ. Mechanisms and Use of Calcium-Sensitizing Agents in the Failing Heart. Circulation 2006; 113(2):305-15.

16. Krum H and Abraham WT. Heart failure. Lancet 2009;  373(9667):941-55.

17. Campia U, Nodari S, Gheorghiade M,Teerlink JR, Metra M, Zacà V et al. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev 2013; 14, 689–96.

18. Overgaard CB, Džavík V. Inotropes and Vasopressors. Circulation 2008; 118(10):1047-56.

19. Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail 2001; 7(2 Suppl 1):8-12.

20. Cuffe MS, Califf RM, Adams KF. Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure: A Randomized Controlled Trial. JAMA 2002; 287(12):1541-7.

21. Pierrakos C, Velissaris D, Franchi F, Muzzi L, Karanikolas M, Scolletta S. Levosimendan in critical illness: a literature review. J Clin Med Res 2014; 6: 75–85.

22. http://www.centerwatch.com/drug-information/fda-approved-drugs accesed in December 2014

23. Bethan H. 2009 FDA drug approvals. Nature Reviews Drug Discoveries 2010; February 9, 89-92

24. Pollesello P. Drug discovery and development for acute heart failure drugs : Are expectations too high ? Int J Cardiol 2014; 172(1):11-3.

25. Dickstein K. Cardiac myosin activation : will theory and practice coincide ? Lancet 2011;  378(9792):639-41. 

26. Leinwand LA and Moss RL. Chemically Tuned Myosin Motors. Science 2011; 331(6023):1392-3.

27. Teerlink JR. A novel approach to improve cardiac performance: Cardiac myosin activators. Heart Fail Rev 2009; 14(4):289-98.

28. Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator , omecamtiv mecarbil : a first-in-man study. Lancet 2011; 378(9792):667-75.

29. Niu C, Cox DR, Lee KH, Sylvester S, Sueoka SH, Qian X et al. Cellular responses of the myosin activator CK689705 in normal and heart failure. Mol Biol Cell 2004; 15:271A.

30. Straight AF, Cheung A, Limouze J, Chen I, Westwood NJ, Sellers JR et al. Dissecting temporal and spatial control of cytokinesis with a myosin II Inhibitor. Science 2003; Mar 14;299(5613):1743-7.

31. Morgan BP, Muci A, Lu P, Qian X, Tochimoto T, Smith WW et al. Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin. ACS Med Chem Lett 2010; 1(9):472-7.

32. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science 2011; 331(6023):1439-43.

33. Wang T, Ajtai K and Burghardt  TP. Analytical Comparison of Natural and Pharmaceutical Ventricular Myosin Activators.Biochemistry 2014; 53(32):5298-306.

34. Shen Y, Malik FI, Zhao X,  Depre C, Dhar SK, Abarzúa P et al. Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart Failure. Circ Heart Fail 2010; 3(4):522-7.

35. Cleland JFG,  Teerlink JR, Senior R, Nifontov EM, McMurray JJV, Lang CC et al.The effects of the cardiac myosin activator , omecamtiv mecarbil , on cardiac function in systolic heart failure : a double-blind , placebo-controlled , crossover , dose-ranging phase 2 trial. Lancet 2011 378(9792):676-83.

36. Teerling JR, Felker M, McMurray JJV, Ponikovski P, Metra M, F. G. et al. ATOMIC-AHF: Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: Results from ATOMIC-AHF; European Society of Cardiology Congress 2013.

37. Garg V and Frishman WH. A new approach to inotropic therapy in the treatment of heart failure: cardiac myosin activators in treatment of HF. Cardiol Rev 2013; 21(3):155-9.

GO BACK to the 2014, October-December issue 
GO BACK to DISCOVERIES 
MEET OUR EDITORIAL BOARD 
SUBMIT A MANUSCRIPT

 Email us at info@discoveriesjournals.org if you have any question.